explore -WSS

explore

author：knowledge 2025-08-06 05:21:36 - browse：318

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Colonoscopy prep: Liquid

knowledge

hotspot

WSS

Plastic surgeons increase patient psychiatric screenings

Maker of FluMist seeks to allow at

Leading voice in opioid treatment defends methadone clinic system

Hospitals warn Medicare's drug payment fix is ‘unlawful’

First Opinion Podcast: How to protect health care in times of war

Positive childhood experiences can help future health

focus

explore

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Telehealth options flood the market as retailers push virtual care

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Heart attack and stroke risk calculators need revising

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Supreme Court strikes down use of affirmative action

SCOTUS questions limit to govt efforts to fight misinformation

Medical leaders decry Supreme Court decision on affirmative action

Leading voice in opioid treatment defends methadone clinic system

hotspot

Positive childhood experiences can help future health

Plastic surgeons increase patient psychiatric screenings

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Testing for cancer recurrence creates a new limbo for patients

Gene editing the human germline: What are the risks?

Colonoscopy prep: Liquid

knowledge

knowledge

hotspot

entertainment